GSK plc
Ownership & governance
Executives 5Directors 10Avg age 64Avg tenure 4.5y
LM
Luke Miels
Chief Executive Officer
Since 2025-12-31
+14
Executives5
LM
Luke Miels
Chief Executive Officer
—Since 2025-12-31
JB
Julie Brown
Director of Finance/CFO
Age 64Since 2023-04-30
SR
Shobie Ramakrishnan
Chief Tech/Sci/R&D Officer
—Since 2021-11-30
JF
James Ford
Compliance Officer
—Since 2018-07-31
TW
Tony Wood
Chief Tech/Sci/R&D Officer
—Since 2022-01-18
Board of directors10
LM
Luke Miels
Director/Board Member
—Since 2026-05-05
HB
Hal Barron
Director/Board Member
Age 64Since 2017-12-31
JS
Jonathan Symonds
Chairman
Age 68Since 2019-08-31
CB
Charles Bancroft
Director/Board Member
Age 66Since 2020-04-30
AB
Anne Beal
Director/Board Member
Age 63Since 2021-05-05
HD
Harry Dietz
Director/Board Member
Age 68Since 2021-12-31
VS
Vishal Sikka
Director/Board Member
Age 59Since 2022-07-17
EA
Elizabeth Anderson
Director/Board Member
Age 68Since 2022-08-31
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Fidelity Management & Research Co. LLC | 5.732 % | 232,229,061 |
| Vanguard Capital Management LLC | 2.795 % | 113,225,855 |
| Dodge & Cox | 2.192 % | 88,816,040 |
| BlackRock Investment Management (UK) Ltd. | 1.779 % | 72,082,936 |
| Schroder Investment Management Ltd. | 1.67 % | 67,667,906 |
Catalog · 2026-07-09
Companies House officers4
| Name | Role | Since | Shares |
|---|---|---|---|
| DMOWSKI, Greg | Director | 1999-11-18 | - |
| WATERLOW NOMINEES LIMITED | Corporate-Nominee-Director | 1999-11-18 | - |
| PURTON-DMOWSKI, Iwona Kasia | Secretary | 1999-11-18 | - |
| WATERLOW SECRETARIES LIMITED | Corporate-Nominee-Secretary | 1999-11-18 | - |
Significant control1
| Name | Nature of control |
|---|---|
| Mr Greg Dmowski | ownership of shares 75 to 100 percent |
Companies House · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| GlaxoSmithKline IHC Ltd. | Regional Banks |
| GlaxoSmithKline Ltd. | Pharmaceuticals: Major |
| GlaxoSmithKline Ltd. | Pharmaceuticals: Major |
| Corixa Corp. | Biotechnology |
| Corixa Corp. | Biotechnology |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 60.51Range 49–70Analysts 9
49Mean 60.5170
- Strong buy 1
- Buy 3
- Hold 4
- Sell 1
Broker actions9
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Barclays | Downgrade | Underweight | — | 2026-01-06 |
| Jefferies | Downgrade | Hold | — | 2024-11-12 |
| Guggenheim | Downgrade | Neutral | — | 2024-10-31 |
| UBS | Downgrade | Neutral | — | 2024-07-08 |
| Jefferies | Maintained | Buy | 53 | 2024-07-02 |
| Goldman Sachs | Initiated | Neutral | 47 | 2024-05-30 |
| Guggenheim | Upgrade | Buy | — | 2024-03-04 |
| Morgan Stanley | Initiated | Equal-Weight | 44 | 2024-01-23 |
| Jefferies | Upgrade | Buy | 48 | 2024-01-03 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.